$1 Million Bet on a Cure: Reprogramming the Immune System to Stop Type 1 Diabetes

Published: January 12, 2026

CHARLESTON, S.C. — In a bold move to transition type 1 diabetes (T1D) from a chronic condition to a curable one, researchers at the Medical University of South Carolina (MUSC) have launched a high-stakes project to “reprogram” the human immune system. Backed by a new $1 million grant from Breakthrough T1D (formerly JDRF), the team aims to utilize engineered “bodyguard” cells to protect lab-grown insulin producers, potentially eliminating the need for daily injections and lifelong immunosuppressant drugs.

The initiative, led by Leonardo Ferreira, Ph.D., an assistant professor at MUSC, marks a significant shift in regenerative medicine. By combining stem cell biology with advanced immunotherapy, the team is attempting to solve the two greatest hurdles in diabetes treatment: the chronic shortage of donor cells and the body’s relentless tendency to reject foreign tissue.

The Biological Civil War: Understanding T1D

Type 1 diabetes is an autoimmune disorder where the body’s defense system mistakenly identifies insulin-producing beta cells in the pancreas as foreign invaders. The resulting “friendly fire” destroys these cells, leaving the body unable to regulate blood sugar.

According to the Centers for Disease Control and Prevention (CDC), approximately 1.5 million Americans live with T1D. Without natural insulin, patients face a lifetime of rigorous glucose monitoring and exogenous insulin delivery. Even with modern pumps and sensors, the risk of long-term complications—including nerve damage, vision loss, and kidney failure—remains a constant shadow.

The “Bodyguard” Solution: How CAR-Treg Therapy Works

Current treatments for severe T1D sometimes involve islet cell transplants from deceased donors. However, this requires patients to take powerful immunosuppressive drugs to prevent rejection. These drugs can weaken the entire immune system, increasing the risk of infections and cancers—a trade-off that is particularly concerning for pediatric patients.

Dr. Ferreira’s approach uses Chimeric Antigen Receptors (CARs) to solve this. His team “reprograms” Regulatory T-cells (Tregs)—the cells naturally responsible for maintaining peace in the immune system.

“These engineered Tregs function like bodyguards with a GPS,” says Ferreira. “We give them a specific ‘key’ that fits a ‘lock’ on the surface of the new beta cells. When they connect, the Treg sends a powerful signal to the rest of the immune system to stand down.”

A Three-Pronged Scientific Alliance

The project is a collaborative effort involving three distinct areas of expertise:

1. Immune Engineering: Dr. Ferreira (MUSC) focuses on the CAR-Treg “bodyguards.”

2. Stem Cell Manufacturing: Holger Russ, Ph.D. (University of Florida), specializes in creating an unlimited supply of beta cells from stem cells, bypassing the need for organ donors.

3. Humanized Modeling: Michael Brehm, Ph.D. (UMass Medical School), utilizes advanced mouse models that mimic human immune responses to test the therapy’s safety and efficacy.

Solving the Supply Chain Crisis

One of the most practical breakthroughs of this research is the move toward “off-the-shelf” therapy. Currently, a single islet transplant often requires cells from three or four human donors.

By using stem-cell-derived islets, the team can manufacture, freeze, and store cells for extended periods. This scalability could transform a rare, difficult-to-access procedure into a standardized treatment available to patients regardless of their disease duration.

“We’re trying to develop a therapy that would work for all people with type 1 diabetes at every stage,” Ferreira noted, “even those who have had the disease for many years and have no beta cells left.”

Challenges and the Road to Clinical Trials

Despite the promising $1 million investment, significant hurdles remain. In preclinical “humanized” mouse models, the protective effect of the engineered Tregs has lasted about one month. The new funding will specifically target how to extend this window and determine if multiple doses can create a permanent “peace treaty” within the body.

Independent experts caution that while the science is sound, “reprogramming” the human immune system is incredibly complex. Issues such as “exhaustion” of the engineered cells or the potential for the CAR-Tregs to suppress the immune system too broadly must be rigorously evaluated in human trials.

Public Health Implications

If successful, this “lock-and-key” mechanism could serve as a blueprint for treating other autoimmune diseases, such as multiple sclerosis or lupus. For the T1D community, it represents the most tangible hope yet for a future without fingerpricks or pumps.

“This can change how medicine is done,” Ferreira said. “Instead of treating symptoms, we can actually replace the missing cells.”

Statistical Snapshot: Type 1 Diabetes in the U.S.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

$1 Million Bet on a Cure: Reprogramming the Immune System To Stop Type 1 Diabetes